2026-06-05T09:03:03-07:00 2025-12-31 931938669 Sacramento Accounting & Advisory Group LLP 1111 Exposition Blvd Ste 100 Sacramento CA 95815 990EZ 2025-01-01 204792248 Neuropathy Action Foundation NEUR 7145509155 1950 Old Tustin Avenue Santa Ana CA 92705 Christopher DeSantis Executive Director 2026-06-05 true Cheryl Mandich CPA P03014274 9169669366 2025 2025-03-06 01:10:19Z X X www.neuropathyaction.org X X 74132 X 65106 9026 0 0 0 0 74132 10511 3723 462 23481 38177 35955 345787 381742 X 347696 382192 347696 382192 1909 450 345787 381742 To educate the general public, healthcare providers, patients and decision makers on what Neuropathy is and to help Neuropathy patients obtain access to individualized treatments. In 2025 the NAF released a white paper titled, Clinical Trials for Neuropathy: Looking Ahead. The paper looks at how clinical trials are developing and why participation remains a critical part of discovering new therapies. We are proud to release Clinical Trials for Neuropathy: Looking Ahead, said Dominick Spatafora, NAF board president. This study helped us take a closer look at whats working, whats emerging, and how we can continue to move toward treating and preventing neuropathy. The report explores the categories that trials are currently underway: medication and biologics, regenerative or gene-related therapies, nerve-stimulation devices, and technology like virtual-reality programs or wearable monitors.The investigation also highlights innovation in the field, including precision medicine, AI tools, and new trial designs that may shorten the time it takes to understand whether a treatment works.Despite the promising aspects of neuropathic treatments, federal funding is a concern. While the biopharmaceutical industry invested more than $200 billion in research and development in 2024, recent federal budget cuts have reduced public funding for neuropathy research. This gap puts greater pressure on private investment and patient participation to keep new therapies moving forward.The study further outlines the importance of patient representation. Many communities especially older adults, women, and people from racial and ethnic minority groups remain underrepresented in neuropathy trials. The paper points out that the reasons are usually practical ones: transportation, lack of clear information, language differences, or simply not knowing a trial exists. Inclusivity is not just a scientific priority; it is a moral one. If we want treatments that work for everyone, then everyone needs a fair chance to participate. Breaking down barriers and expanding outreach will make future therapies stronger, safer, and more effective.The paper closes by encouraging more conversation between clinicians, caregivers, and patients. Community groups and advocates can also help by sharing trustworthy trial information and encouraging more people to ask questions. To access the full white paper, please visit www.neuropathyaction.org.Additionally, since its founding in 2006, the NAF has remained committed to providing neuropathy patients with essential resources to access individualized medications, IVIG, and other treatments through patient empowerment and strategic advocacy. To this end, in 2025 the NAF: Broadened our participation in national and state coalitions to maximize our impact. o To this end the NAF was part of eighteen various state and national coalitions in 2025. Expanded advocacy efforts beyond the states to national issues that impact patient access to medications, impact affordability, and research efforts. o To this end the NAF had over fifty engagements on various federal issues that impacted neuropathy awareness, funding, or access to treatments/medications. Continued our focus on state policy ensuring patients are protected from copay diversion programs, step therapy, prior authorizations, non-medical switching, and other harmful third party (health plan, government, PBM, etc.) practices. o To this end the NAF had over one hundred engagements in the states on various awareness, education, and access issues. 26724 26724 Dominick V Spatafora President 11.50 0 Christopher DeSantis Executive Dir. 4.00 0 James D Lee JD Director 1.50 0 Dustin Corcoran Director 0.25 0 Leslie Macgregor Director 1.50 0 Jonathan Medeiros Director 0 0 Christopher Buchanan Director 0 0 Richard S Zimmerman MD Director 0.23 0 Kathleen S Creason Treasurer 0.23 0 Sarah J Fullerton Secretary 0 0 false false false false false false false 0 0 0 false 0 0 false CA DeSantis Management Group 1950 Old Tustin Ave Santa Ana CA 92705 7145509155 false false false false false false false false false false false NONE DeSantis Management Group 1950 Old Tustin Ave Santa Ana CA 92705 Manangement Fees 10875 true X 55702 69458 54886 73114 65106 318266 0 0 0 0 55702 69458 54886 73114 65106 318266 0 0 318266 16 42 265 323 0 16 42 265 323 0 0 55718 69500 55151 73114 65106 318589 0.99900 0.99910 0.00100 0.00090 X Other Expenses.1001 Advertising and Promotion $884 Other Expenses.1003 Information Technology $2865 Other Expenses.1006 Payments of Travel or Entertainment for Public Officials $1361 Other Expenses.1012 Insurance $411 Other Expenses.1 Patient Education/Awareness $12491 Other Expenses.2 Patient Relations & Advocacy $5261 Other Expenses.5 Repairs & Maintenance $108 Other Expenses.6 Taxes & Licenses $100 Total Liabilities.1001 Accounts Payable and Accrued Expenses - Beginning $1909 Accounts Payable and Accrued Expenses - Ending $450 Form 990-EZ, Part III, LIne 31 Other program services The NAF continued its bi-monthly Patient Voice newsletters that go out to patient, caregivers, providers, and others worldwide.Helped over two hundred patients with medication access issues.Received 1,409 emails and 271 voice messages and assisted these patients and/or caregivers by directly answering their questions. The NAF mailed out links or pamphlets to over 475 individuals. The NAF partnered with over twenty organizations (companies, universities, researchers, etc.) in an attempt to obtain patients and/or providers to participate in various research studies, grant opportunities, or patient surveys.In 2025, the NAF has 1.55M visitors to its website (www.neuropathyaction.org) and patient brochures the NAF reached millions of patients and interested parties obtain the necessary resources, information, and tools to access individualized treatment to improve their quality of life.Participated in various state and federal advocacy campaigns.Significantly increased our social media presence in an attempt to reach more patients and caregivers. NAF now has 3,700 followers on Facebook and 1,500 followers on Twitter (X)